Site Search

ALBANY, NY – A coalition of more than 65 patient and provider groups, cancer centers, and other public health organizations delivered a letter to state legislative leaders ... in support of legislation that would require insurance plans to cover colorectal cancer screening beginning at age 45 and eliminate all patient cost-sharing for a follow up colonoscopy. Colorectal cancer is the third leading cause of death for men and women in New York. In 2022, an ... as the next step in the preventive screening process and therefore should be covered by health insurers with no patient out-of-pocket cost. ACS CAN is calling on state leaders to include S906-B sponsored by Senators Sanders and Kennedy and A2085-A sponsored by Assemblymember Dinowitz—the ...

... 13 million more Americans being uninsured by 2027 and would increase premiums by 10 percent annually. The bill does, however preserve a portion of the orphan drug tax credit, which is used to encourage development of new treatments for relatively rare conditions, including many cancers. It ... for those who incur high medical costs. A statement from Chris Hansen, president of the American Cancer Society Cancer Action Network (ACS CAN) follows: “Today’s repeal of the individual mandate without a replacement sets the stage toward transforming the individual insurance ... Senators Alexander (R-Tenn.) and Murray’s (D-Wash.) and Senators Collins (R-ME) and Nelson’s (D-Fla.) bipartisan bills that would restore cost-sharing subsidies, as well as provide additional funding to help compensate insurers for their costlier patients through reinsurance. These ...

Early detection of breast and cervical cancer through screening can improve survival and reduce mortality by finding cancer at an early stage when treatment is more effective and less expensive. However, ... has shown there are many barriers to cancer screening for people with limited income, including access to providers and facilities, costs of screening and care, lack of knowledge and understanding about the role of screening, as well as barriers like time off work and access to ...

... DC -- November 16, 2015 -- The Food & Drug Administration (FDA) released a report this afternoon looking at the evidence supporting oversight of lab-developed tests. See the link below to the report and an FDA blog post. Beneath those is a statement from the American Cancer Society Cancer Action Network (ACS CAN): http://blogs.fda.gov/fdavoice/ index.php/2015/11/why-fda- should-oversee-laboratory- developed-tests/ Statement from ACS CAN: The FDA report provides examples of how a lack of oversight of laboratory developed tests can result in misdiagnoses that can have life-threatening consequences. False results, or ...